Dana-Farber Study Shows Predictive Potential of Ignite Proteomics’ RPPA Platform for Enhertu® (T-DXd) in Metastatic Breast Cancer
Aditxt Inc. has announced a notable scientific and clinical milestone involving its precision oncology subsidiary, Ignite Proteomics. The subsidiary has been featured in a peer-reviewed study published online ahead of print in npj Precision Oncology, a respected publication within the Nature portfolio. The research, led by investigators at the Dana-Farber Cancer Institute, examined treatment outcomes in patients with metastatic breast cancer receiving the antibody-drug conjugate Enhertu, while also evaluating the predictive performance of various HER2-related biomarker assays.
The study addresses a long-standing challenge in oncology: the difficulty of accurately predicting which patients will benefit from a given therapy. While Enhertu has emerged as a widely used treatment option for patients with metastatic breast cancer—including those with varying levels of HER2 expression—there remains no consistently reliable method for identifying responders in advance. This gap often leads to a trial-and-error approach in treatment selection, exposing patients to therapies that may ultimately provide limited or no benefit.
Traditionally, HER2 status has been assessed using immunohistochemistry (IHC), a method that classifies tumors based on protein expression levels. While IHC has been instrumental in guiding treatment decisions for years, it has inherent limitations. It typically provides a categorical rather than quantitative view of HER2 expression and does not capture the broader biological context of the tumor, including signaling pathways or the presence of other relevant protein markers.
In the Dana-Farber-led study, researchers compared conventional HER2 IHC with a range of quantitative HER2-related assays to determine their association with clinical outcomes. While IHC showed some correlation with treatment response across the overall patient population, its predictive power was limited in certain biomarker-defined subgroups. In contrast, quantitative assays demonstrated a greater ability to provide nuanced and clinically meaningful insights, particularly within matched sub-cohorts of patients.
Among the technologies evaluated, Ignite Proteomics’ Reverse Phase Protein Array (RPPA) platform stood out as the only commercially available multiplex assay included in the study. The platform demonstrated meaningful predictive value in identifying patient outcomes, particularly in scenarios where traditional HER2 testing fell short. By enabling simultaneous measurement of multiple protein biomarkers from a single tumor sample, RPPA offers a more comprehensive view of tumor biology.
Unlike single-marker tests, RPPA captures information about protein expression, pathway activation, and biomarkers related to the mechanism of action of specific therapies. This multidimensional approach allows clinicians and researchers to better understand how a tumor is likely to respond to treatment. In the context of the study, this capability proved especially valuable in identifying patterns that were not apparent through HER2 IHC alone.
One of the most significant findings involved the detection of TOPO1 expression, the molecular target of Enhertu’s cytotoxic payload. The RPPA platform was able to identify TOPO1 expression in certain patients who were classified as HER2-negative by traditional testing. This observation suggests that some patients who would not typically be considered candidates for HER2-targeted therapy may still derive benefit based on underlying tumor biology. It highlights the importance of looking beyond surface-level biomarkers to better align treatment strategies with the mechanisms driving tumor response.
The broader implications of these findings are substantial. In oncology, it is well documented that a significant proportion of patients do not respond to therapies that are otherwise considered standard of care. Various studies have highlighted this issue across treatment modalities. For example, research has shown that many cancer drugs enter the market without definitive evidence of improved survival or quality-of-life benefits. Similarly, targeted therapies and immunotherapies often demonstrate variable response rates, reflecting the complexity and heterogeneity of cancer.
Ignite Proteomics’ leadership has emphasized that this variability is not necessarily a reflection of the therapies themselves, many of which are highly effective in the right patients. Rather, the challenge lies in selecting the appropriate treatment for each individual based on the unique biological characteristics of their tumor. Current diagnostic approaches, which often rely on single biomarkers, may fail to capture this complexity.
The RPPA platform was specifically developed to address this gap. By measuring multiple proteins and signaling pathways simultaneously, it provides a more functional assessment of tumor biology. This approach aligns with the growing emphasis on precision medicine, where treatment decisions are guided by detailed molecular and biological data rather than broad classifications.
Importantly, Ignite’s RPPA assay is already positioned for clinical use. It is CLIA-certified and CAP-accredited, indicating compliance with rigorous standards for laboratory testing. It is also listed on the Medicare Clinical Laboratory Fee Schedule under an established CPT code, making it accessible for ordering using standard biopsy tissue samples. This readiness for clinical deployment distinguishes it from many emerging technologies that remain confined to research settings.
From a strategic perspective, the publication of these findings in a high-impact, peer-reviewed journal represents a critical validation for both Ignite Proteomics and its parent company, Aditxt. Peer-reviewed evidence from a leading institution like Dana-Farber carries significant weight in the medical community and can play a key role in accelerating adoption of new diagnostic tools.
Aditxt’s leadership has highlighted the importance of this milestone in advancing its broader mission. As a company focused on accelerating health innovations, Aditxt aims to identify and scale technologies that have the potential to improve patient outcomes. The success of Ignite’s RPPA platform in this study aligns with that objective, demonstrating how advanced diagnostics can address unmet needs in oncology.
The findings also come at a time when the field of precision oncology is rapidly evolving. As new therapies—including antibody-drug conjugates, targeted agents, and immunotherapies—continue to emerge, the need for more sophisticated diagnostic tools is becoming increasingly urgent. Without accurate methods for predicting response, the full potential of these therapies cannot be realized.
By providing deeper insights into tumor biology, multiplex platforms like RPPA could help bridge this gap. They offer the possibility of more informed treatment selection, reducing the likelihood that patients will receive therapies unlikely to benefit them. This not only has implications for clinical outcomes but also for healthcare efficiency, as it may reduce unnecessary treatments and associated costs.
In summary, the Dana-Farber study highlights the limitations of traditional HER2 testing and underscores the value of quantitative, multiplex approaches in predicting treatment response. Ignite Proteomics’ RPPA platform demonstrated its ability to deliver clinically relevant insights, particularly in patient subgroups where conventional methods fall short. For Aditxt Inc., this achievement represents a meaningful step forward in its efforts to bring impactful innovations to market.
As oncology continues to move toward more personalized treatment strategies, technologies that can accurately capture the complexity of tumor biology will play an increasingly central role. The evidence presented in this study suggests that multiplex proteomic approaches may be a key part of that future, helping to ensure that more patients receive the right therapy at the right time.
About Ignite Proteomics, LLC
Ignite Proteomics delivers pathway‑level protein analytics to guide precision oncology. Operating a CLIA‑certified, CAP‑accredited laboratory, Ignite’s clinical RPPA assay quantifies 32 phospho- and total-protein biomarkers from limited biopsy material to support oncology research and clinical decision making.
About Aditxt, Inc.
Aditxt, Inc. is a social innovation platform accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners, and shareholders collaboratively drives its mission to “Make Promising Innovations Possible Together.” The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress. The Company currently operates four programs focused on autoimmunity, cancer and early disease detection, infectious diseases and women’s health.
Source Link:https://www.businesswire.com/
